Cisplatin versus carboplatin in small cell lung cancer (SCLC): Single-center experience.

e20116 Background: The current standard of care for the treatment of SCLC is concurrent chemoradiatiotherapy for patients with limited-stage and chemoimmunotherapy for extensive-stage SCLC. Cisplatin is the preferred platinum agent in both settings. Although cisplatin constitutes the standard treatment with level one evidence, carboplatin is preferred in daily practice due to its more reliable toxicity profile. Methods: To investigate carboplatin is not inferior to cisplatin in both settings we retrospectively analyzed our data between 2011-2021. The results were given HR, 95% CI, and p-value. Kaplan-Meier survival analyses with log-rank tests were performed to examine and compare OS. Results: Overall 113 patients were analyzed. 62 (54.9%) patients received carboplatin+etoposide and 51 (45.1%) patients had cisplatin+etoposide. Median age was 70 vs 59.5 in carboplatin and cisplatin patients, respectively (p < 0.001). Multivariate analyses showed that patients who received carboplatin had worse ECOG PS (p = 0.011). Median OS in both groups (Carbo vs Cis) were similar in limited stage (29.37 vs 27.77 mos p = 0.52) and extensive stage (10.79 vs 9.83 mos p = 0.64). Conclusions: Although cisplatin is still a backbone drug in both limited and extensive stage SCLC, carboplatin is a preferable drug due to its similar survival and tolerable toxicity advantage.